Women Want Strong Men
Semaglutide - A Game Changing Weight-Loss Medication Explained With Dr. David Yablonsky
Semaglutide has recently been proven to induce significant weight loss in patients with obesity that is sustained for as long as the drug is given. Much attention has been given recently to Semaglutide in both scientific circles and in the media because of a landmark article in the New England Journal of Medicine addressing the impact of this medication in a large clinical trial. To explain this medication in detail and how and why it works I have Dr. David Yablonksy on this show.
Topics Discussed Include:
What is Semaglutide?
What weight loss medications are on the market?
Side effect profiles of the weight loss medication on the market?
How much weight are patients losing on Semaglutide?
How much does the drug cost? Commercial vs compounding
Tirzepatide a competitor and how is it performing in clinical trials?
How the gut-brain signals, and the concept of a microbiome–gut–brain axis.
Studies:
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
Wegovy (semaglutide): a new weight loss drug for chronic weight management
More about Dr. Yablonsky:
Dr. David Yablonsky has been practicing medicine for over 20 years and is a board-certified internist. Dr. Yablonsky has experience in providing adults with help diagnosing a full range of medical issues including chronic disease management, primary care, hormone optimization, erectile dysfunction, weight loss and vitamin deficiencies. Dr. Yablonsky graduated with honors from Boston University prior to attending the Des Moines University College of Osteopathic Medicine. Upon completion of medical school, he went on to complete a three-year residency in Internal Medicine at the University of Rochester School of Medicine in Rochester, New York. His past leadership positions include Chief of Medicine, Internal Medicine Section Chief, Medical Director of Cardiopulmonary Rehabilitation and Chairman of Pharmacy and Therapeutics Committee at Grinnell Regional Medical Center in Grinnell, Iowa. Dr. Yablonsky’s focus is on disease prevention and health optimization. He has furthered his training by completing several conferences and courses in age management medicine including the elite training programs of Cenegenics, A4M, AMMG, and the International Peptide Society.
For questions about today's podcast you can contact Amy Stuttle at podcast@amystuttle.com
Click here to learn more about Victory Men's Health
Semaglutide has recently been proven to induce significant weight loss in patients with obesity that is sustained for as long as the drug is given. Much attention has been given recently to Semaglutide in both scientific circles and in the media because of a landmark article in the New England Journal of Medicine addressing the impact of this medication in a large clinical trial. To explain this medication in detail and how and why it works I have Dr. David Yablonksy on this show.
Topics Discussed Include:
What is Semaglutide?
What weight loss medications are on the market?
Side effect profiles of the weight loss medication on the market?
How much weight are patients losing on Semaglutide?
How much does the drug cost? Commercial vs compounding
Tirzepatide a competitor and how is it performing in clinical trials?
How the gut-brain signals, and the concept of a microbiome–gut–brain axis.
The impact obesity has on our society.
Commercial Brands Include:
Ozempic — approved in 2014 for lowering blood glucose and HBA1C in type 2 diabetics as a once-a-week subcutaneous injection
Rybelsus — approved in 2019 as the once-a-day oral formulation of Ozempic
Wegovy — approved on June 4, 2021 for chronic weight management in overweight patients (BMI > 27 kg/m2) with one weight-loss related ailment (ex. diabetes), or obese patients (BMI > 30 kg/m2)
Studies:
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
Wegovy (semaglutide): a new weight loss drug for chronic weight management
More about Dr. Yablonsky:
Dr. David Yablonsky has been practicing medicine for over 20 years and is a board-certified internist. Dr. Yablonsky has experience in providing adults with help diagnosing a full range of medical issues including chronic disease management, primary care, hormone optimization, erectile dysfunction, weight loss and vitamin deficiencies. Dr. Yablonsky graduated with honors from Boston University prior to attending the Des Moines University College of Osteopathic Medicine. Upon completion of medical school, he went on to complete a three-year residency in Internal Medicine at the University of Rochester School of Medicine in Rochester, New York. His past leadership positions include Chief of Medicine, Internal Medicine Section Chief, Medical Director of Cardiopulmonary Rehabilitation and Chairman of Pharmacy and Therapeutics Committee at Grinnell Regional Medical Center in Grinnell, Iowa. Dr. Yablonsky’s focus is on disease prevention and health optimization. He has furthered his training by completing several conferences and courses in age management medicine including the elite training programs of Cenegenics, A4M, AMMG, and the International Peptide Society.
For questions about today's podcast you can contact Amy Stuttle at podcast@amystuttle.com
Click here to learn more about Victory Men's Health